Combined treatment with curcumin and docetaxel has been reported to modulate the expression of RTKs, PI3K, phospho-AKT, NF-kappa B, p53, and COX-2, which signifies the potential of curcumin to serve as a potential therapeutic contender in enhancing the efficacy of docetaxel in prostate cancer treatment [230]. The gene discussed is TP53; the disease is prostate carcinoma.